



# Targeting GPCR-signaling via allosteric control of regulatory proteins

Hossein Mohammadiarani and Harish Vashisth



SUPPORT: National Science Foundation  
CHE—1508595

Department of Chemical Engineering, University of New Hampshire, Durham, NH

## Abstract

Regulators of G protein signaling (RGS) proteins modulate GPCR signaling by binding to  $\alpha$ -subunits of heterotrimeric G proteins and accelerating hydrolysis of GTP. Therefore, RGS proteins are becoming increasingly important therapeutic targets to be directly or allosterically inhibited from binding to  $\alpha$ -subunits. While structures of several known RGS proteins are highly similar and largely contain  $\alpha$ -helical motifs, some *thiadiazolidinone* (TDZD) compounds that target cysteine residues have shown different levels of specificities and potencies for closely related proteins thereby suggesting intrinsic differences in dynamics of these proteins. In this work, we have studied the dynamics of three different RGS proteins (apo-RGS4, apo-RGS8, and apo-RGS19) using microsecond-scale classical molecular dynamics (MD) simulations with CHARMM and AMBER force-fields. Analyses of these trajectories reveal high fluctuations in  $\alpha 5$  and  $\alpha 6$  helices and the loops connecting them. These fluctuations lead to perturbations in residues in the RGS- $\alpha$  interface and in the vicinity of cysteines that are targets of allosteric inhibitors. These findings have significant implications for understanding differences in potencies and specificities of inhibitory small-molecules.


## Methods and Software

**NAMD** (NANoscale Molecular Dynamics) is a parallel molecular dynamics code designed for high performance simulation of large systems of particles based on Newtonian equation of motion:

$$m_i \ddot{r}_i = - \frac{\partial}{\partial r} U_{total} \quad i = 1, 2, 3, \dots, N$$

$$U_{total} = U_{bond} + U_{angle} + U_{dihedral} + U_{vdw} + U_{coulomb}$$

$$U_{coulomb} = \frac{q_1 q_2}{4\pi\epsilon_0 r_{12}} \quad U_{vdw} = 4\epsilon_{12} \left[ \left( \frac{\sigma_{12}}{r_{12}} \right)^{12} - \left( \frac{\sigma_{12}}{r_{12}} \right)^6 \right]$$



$$U_{dihedral} = k_a(1 + \cos(n\phi - \gamma)) \quad U_{angle} = k_a(\theta - \theta_0)^2 \quad U_{bond} = k_b(r - r_0)^2$$

**VMD** (Visual Molecular Dynamics) is a molecular visualization software for displaying and analyzing MD simulations.


## Role of RGS Proteins in GPCR Signaling

As being key components of GPCR signal transduction


Bind directly to the GTP-bound  $\alpha$  subunit

Markedly accelerate the rate of GTP hydrolysis

Accelerate the rate of inactivation of GPCR signaling



## Structure and Sequence of RGS Protein



Cartoon representations of the box domain of RGS4 (1AGR)

## MD Simulations of RGS Proteins (RGS4, RGS8, RGS19)

Equilibration simulation parameters:


- ✓ RGS immersed in water box (~70 Å x ~65 Å x ~65 Å)
- ✓ Neutralized in saline water (0.05 mol/L KCl)
- ✓ Periodic boundary conditions
- ✓ Number of atoms: ~29000 atoms

Equilibration steps:


- 1- 0.4 ns in NPT ensemble
- 2- ~ 1.5  $\mu$ s in NVT ensemble

Force fields:


- ✓ CHARMM force filed (CHARMM36, tip3p)
- ✓ AMBER force filed (ff14SB, tip3p)



## Simulation Results




## Small Molecule Inhibitors of RGS




Thiadiazolidinone (TDZD) Analogues [5]

Inhibitor of RGS proteins that blocks a protein-protein interaction (RGS- $\alpha$ ) in screening assay.



CCG50014  
RGS4 IC<sub>50</sub> 30.1 nM  
RGS8 IC<sub>50</sub> 11.0  $\mu$ M  
Selective RGS4 inhibitor [5]



Simulations of RGS4 interaction with the selective inhibitor (CCG50014). Only the sulphur atoms of the drug are shown. The drug mostly interacts with  $\alpha 5$  and  $\alpha 6$  helices and the connecting loops.

## References and Acknowledgements

1. J. C. Phillips, et al., 2005, J. Comp. Chem., 26:1781-1802
  2. W. Humphrey, et al., 1996, J. Mol. Graphics, 14:33-38
  3. H. Vashisth, et al. 2013, ACS Chem. Biol. 8.12:2778-2784.
  4. R. Neubig, et al, 2002, Nat. Rev. Drug Discov. 1.3:187-197.
  5. E. M. Turner, et al., 2011, ACS Med. Chem. Lett. 3.2:146-150.
- We acknowledge financial support from the National Science Foundation (#1508595) and computational resources through NSF XSEDE mechanism (#TG-MCB140029) and a Cray supercomputer at UNH (supported via NSF#PHY-1229408).